PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia.\', \'Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia.\', \'Department of Laboratory Immunology, Clinical Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia.\', \'Department of Physiology and Immunology, School of Medicine, University of Zagreb, Zagreb, Croatia.\', \'Department of Laboratory Immunology, Clinical Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia; Department of Physiology and Immunology, School of Medicine, University of Zagreb, Zagreb, Croatia.\', \'Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia; Faculty of Electrical Engineering and Computing, University of Zagreb, Zagreb, Croatia.\', \'Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia. Electronic address: mhabek@mef.hr.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S2211-0348(20)30778-110.1016/j.msard.2020.102704
?:hasPublicationType
?:journal
  • Multiple sclerosis and related disorders
is ?:pmid of
?:pmid
?:pmid
  • 33370649
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.123
?:rankingScore_hIndex
  • 18
is ?:relation_isRelatedTo_publication of
?:title
  • Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all